P292 Adjuvant endocrine therapy in stage I breast cancer in a regional oncology practice after the introduction of aromatase inhibitors as a universal health benefit in Israel Academic Article uri icon

abstract

  • prescribed As (<13 weeks duration). All pts received As (1mg orally/day) in a Medication Event Monitoring System (MEMS® AARDEX Ltd). MEMS is an electronic medication event monitor consisting of a 500 ml bottle with a threaded closure containing the electronic, time-stamping microcircuitry. The date and time are automatically recorded at each opening of the container. The 500 ml capacity contains the necessary medication for 6mo treatment and avoids additional clinical visits to resupply medication. Results: 107 pts (mean age ±SD 61.2 y ±10.0) were enrolled: 54 in GpA, 53 in GpB. 53 pts received chemotherapy: 10 pts had neo-adjuvant chemotherapy and 44 had post-operative chemotherapy. Only 16 pts (15.8%) were receiving another treatment for early BC. Adherence to As will be estimated as the daily proportion of patients taking As. Secondary variables will include persistence with As, execution of As regimen and reasons for treatment discontinuation. Conclusion: This study began recruitment in July 2009, is ongoing and will be completed in December 2010.Using the innovative MEMS approach, the results of this study will assess compliance in early BC. Disclosure of Interest: J.-M. Nogaret: None Declared, T. Vanlerberghe Employee of AstraZeneca

publication date

  • January 1, 2011